resource-center Topics Terms-of-Service 
Pharma Marketing Network
MARCH 25, 2022
Before being called upon as a resource for family or friends, the caregivers themselves may be unaware of the enormity of the impending commitment or the value of a support system during their service. While caregiving can be rewarding, a long-term care commitment may impede the caregiver’s ability to work and socialize.
Putting Patients First Blog
JULY 3, 2023
Created by and for patient organizations over 100 years ago, the NHC brings diverse organizations together to forge consensus and drive patient-centered health policy. We promote increased access to affordable, high-value, equitable, and sustainable health care. The NHC commends the CMS for these provisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ID Stewardship
APRIL 13, 2023
PACCARB provides advice, information, and recommendations to the Health and Human Services Secretary (HHS) regarding programs and policies intended to support and evaluate the implementation of U.S. The regulatory body the Center for Medicare and Medicaid Services (CMS) is one of these departments. Gauthier, Pharm.D.,
The Physician Pharmacist
OCTOBER 19, 2023
link] Our conversation with Dr. Smith covers a wide array of topics that will resonate with aspiring medical professionals and pharmacy enthusiasts alike: Applying to Medical School as a Pharmacy Applicant : Discover the unique considerations and challenges that pharmacy applicants face when making the transition to medical school.
Proxsys Rx
APRIL 19, 2024
In response, The Centers for Medicare & Medicaid Services ( CMS ) issued a proposed remedy for covered entities whose 340B payments were wrongly reduced in calendar years 2018-22. What it means for your 340B program. Either way, I see even more confusion coming, where 340B manufacturer restrictions are concerned.”
Proxsys Rx
JANUARY 10, 2023
The program enables eligible hospitals to serve their communities by stretching ‘scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.’” Because a significantly higher-than-average percentage of their healthcare services are offered to patients who can’t afford to pay.
PharmaShots
APRIL 26, 2023
Under the terms of the Antibody License and Collaboration Agreement, Sanofi is responsible for funding 80% to 100% of the agreed-upon development costs. Dupixent has been Sanofi’s major product in terms of sales, accounting for 19.3% mL, 100 mg/0.67 mL Single-Dose Pre-filled pen Injection: 300 mg/2 mL, 200 mg/1.14
Expert insights. Personalized for you.
98 
Let's personalize your content